New therapeutic strategy for small-cell lung cancer

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K09174
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Respiratory organ internal medicine
• Research Institution: Shimane University
• Principal Investigator: Isobe Takeshi 島根大学, 医学部, 教授 (70284198)
• Co-Investigator(Kenkyū-buntansha): 津端 由佳里 島根大学, 医学部, 講師 (50643417) ; 須谷 顕尚 埼玉医科大学, 医学部, 講師 (80306290) ; 沖本 民生 島根大学, 医学部, 助教 (00733586) ; 濱口 俊一 島根大学, 医学部, 助教 (70609354)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 肺癌 / 小細胞癌 / 血管新生

Outline of Final Research Achievements

Small-cell lung cancer (SCLC) conveys a poor prognosis due to the limited efficacy of existing treatment strategies. To provide clinically relevant strategies for studying new therapeutics and tumor biology, we established a reproducible orthotopic model of human SCLC cells in the nude mouse. (Isobe T: J Thorac Oncol 2013)
Human SCLC cell (N417) was injected into the lung of nude mice. The mice were randomly assigned to receive one of the following three treatments (8 mice in each treatment group): 1) injection per week of CPT-11, 2) daily injection of low-dose CPT-11, 3) control group. The mice were then examined daily for evidence of tumor development. Daily CPT-11 treatment resulted in an increase of apoptosis and decrease of proliferation both tumor cells and tumor related endothelial cells. The development of our orthotopic model of SCLC provide a means for a better understanding the biology of SCLC and will enable evaluation of novel therapeutic strategies.

Free Research Field

呼吸器病学